<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093014</url>
  </required_header>
  <id_info>
    <org_study_id>B7097-R</org_study_id>
    <nct_id>NCT01093014</nct_id>
  </id_info>
  <brief_title>Novel Intervention to Influence Muscle Plasticity in Veterans</brief_title>
  <official_title>Novel Intervention to Influence Muscle Plasticity in Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The loss of muscle contraction (paralysis) removes an important stimulus for maintenance of
      overall health for individuals with complete spinal cord injury (SCI). Increased protein
      catabolism (atrophy) limits important stresses to the skeletal system. Bone loss doubles the
      risk of fracture and contributes to increased mortality in Veterans with SCI. Metabolic
      syndrome and diabetes lead to heart disease in Veterans with SCI at higher rates than the
      general population. Exercise methods to sustain muscle tissue, bone density, and metabolic
      stability after SCI are lacking scientific justification. If left unchecked, the secondary
      complications of SCI can be health limiting or even life threatening to Veterans with
      paralysis. The importance of maintaining the health of the musculoskeletal system after SCI
      has never been greater as a cure for paralysis may become a reality. Contemporary
      rehabilitation interventions lack the ability to functionally load muscle tissue, quantify
      the dose of load, stress the cardiovascular system, monitor the overall stresses during daily
      exercise training, or offer portability to improve compliance with the exercise. The
      long-term goal of this project is to establish the optimal dose of muscle and bone stress
      during functional exercise in order to improve the health of Veterans with complete
      paralysis. The practical outcome of this research is to offer a form of activity that is
      feasible, portable, and grounded in sound scientific principles. The scientific goal is to
      understand whether the dose of force generated in paralyzed muscle via evoked contractions is
      critical to muscle atrophy/hypertrophy molecular pathways, physiologic performance, and
      insulin sensitivity. The investigators will administer various doses of muscle force by
      manipulating the frequency of electrical stimulation while keeping stimulation current (i.e.
      muscle fiber recruitment) constant. Interestingly, no previous study has examined the dose of
      muscle force necessary to trigger adaptations in protein synthesis/degradation pathways. The
      investigators wish to discover the most effective method to maintain the molecular and
      physiologic properties of paralyzed muscle. The investigators believe such a method will be
      in urgent demand as a co-intervention with pharmaceutical strategies in post-SCI
      rehabilitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central Hypothesis: The investigators hypothesize that high muscle force induced via a novel,
      portable, active standing intervention will increase muscle force properties, alter gene
      expression for atrophy and fiber type pathways, and improve systemic insulin sensitivity in
      Veterans with complete paralysis.

      Aim 1: To determine the training effects of 3 tiers of quadriceps muscle force on muscle
      physiological properties in Veterans with chronic paralysis from SCI.

      Aim 2: To determine the training effects of 3 tiers of quadriceps muscle forces on muscle
      mRNA for genes associated with atrophy and muscle fiber type in Veterans with complete
      paralysis.

      Aim 3: To determine the training effects of 2 tiers of compressive load induced by quadriceps
      muscle forces on insulin sensitivity and markers of inflammation in Veterans with SCI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HF Muscle Force</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Muscle force evoked during high-force muscle stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LF Muscle Force</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Muscle force evoked during low-force muscle stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal Muscle Gene Regulation: MSTN</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Messenger ribonucleic acid (mRNA) expression fold-change for myostatin (MSTN). Fold change: post-intervention expression / pre-intervention expression. Values greater than 1.0 indicate up-regulation. Values less than 1.0 indicate down-regulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal Muscle Gene Expression: PPARGC1A</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Messenger ribonucleic acid (mRNA) expression fold-change for peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PPARGC1A). Fold change: post-intervention expression / pre-intervention expression. Values greater than 1.0 indicate up-regulation. Values less than 1.0 indicate down-regulation.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>Arm 1: High-force muscle stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-force muscle stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Low-force muscle stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-force muscle stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Sequential low-force and high-force muscle stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential low-force and high-force muscle stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low-force muscle stimulation</intervention_name>
    <description>Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.</description>
    <arm_group_label>Arm 2: Low-force muscle stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>High-force muscle stimulation</intervention_name>
    <description>Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.</description>
    <arm_group_label>Arm 1: High-force muscle stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sequential low-force and high-force muscle stimulation</intervention_name>
    <description>Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.</description>
    <arm_group_label>Arm 3: Sequential low-force and high-force muscle stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria for all subjects will be upper motor neuron lesions between the
             10th thoracic and the 7th cervical spinal levels. The completeness of the injury will
             be verified by somatosensory evoked potentials.

        Exclusion Criteria:

          -  Subjects will be excluded if they have pressure ulcers

          -  chronic infection

          -  lower extremity muscle contractures

          -  deep vein thrombosis

          -  recent limb fractures

          -  muscle metabolic disorders

          -  any comorbid disease known to affect bone metabolism (such as parathyroid dysfunction)

          -  or if they are pregnant or plan to become pregnant.

          -  Subjects with distal femur trabecular bone mineral density less than 50 mg/cm3 will be
             excluded from participation in quadriceps electrical stimulation training
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K Shields, PhD PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iowa City VA Health Care System, Iowa City, IA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iowa City VA Health Care System, Iowa City, IA</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246-2208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adams CM, Suneja M, Dudley-Javoroski S, Shields RK. Altered mRNA expression after long-term soleus electrical stimulation training in humans with paralysis. Muscle Nerve. 2011 Jan;43(1):65-75. doi: 10.1002/mus.21831.</citation>
    <PMID>21171097</PMID>
  </reference>
  <reference>
    <citation>Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, Malmberg SE, Alipour F, Shields RK, Adams CM. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab. 2011 Jun 8;13(6):627-38. doi: 10.1016/j.cmet.2011.03.020.</citation>
    <PMID>21641545</PMID>
  </reference>
  <reference>
    <citation>McHenry CL, Shields RK. A biomechanical analysis of exercise in standing, supine, and seated positions: Implications for individuals with spinal cord injury. J Spinal Cord Med. 2012 May;35(3):140-7. doi: 10.1179/2045772312Y.0000000011.</citation>
    <PMID>22507023</PMID>
  </reference>
  <reference>
    <citation>Dudley-Javoroski S, Shields RK. Regional cortical and trabecular bone loss after spinal cord injury. J Rehabil Res Dev. 2012;49(9):1365-76.</citation>
    <PMID>23408218</PMID>
  </reference>
  <results_reference>
    <citation>Dudley-Javoroski S, Saha PK, Liang G, Li C, Gao Z, Shields RK. High dose compressive loads attenuate bone mineral loss in humans with spinal cord injury. Osteoporos Int. 2012 Sep;23(9):2335-46. doi: 10.1007/s00198-011-1879-4. Epub 2011 Dec 21.</citation>
    <PMID>22187008</PMID>
  </results_reference>
  <results_reference>
    <citation>Petrie MA, Suneja M, Faidley E, Shields RK. Low force contractions induce fatigue consistent with muscle mRNA expression in people with spinal cord injury. Physiol Rep. 2014 Feb 25;2(2):e00248. doi: 10.1002/phy2.248. eCollection 2014 Feb 1.</citation>
    <PMID>24744911</PMID>
  </results_reference>
  <results_reference>
    <citation>Petrie MA, Suneja M, Faidley E, Shields RK. A minimal dose of electrically induced muscle activity regulates distinct gene signaling pathways in humans with spinal cord injury. PLoS One. 2014 Dec 22;9(12):e115791. doi: 10.1371/journal.pone.0115791. eCollection 2014.</citation>
    <PMID>25531450</PMID>
  </results_reference>
  <results_reference>
    <citation>Petrie M, Suneja M, Shields RK. Low-frequency stimulation regulates metabolic gene expression in paralyzed muscle. J Appl Physiol (1985). 2015 Mar 15;118(6):723-31. doi: 10.1152/japplphysiol.00628.2014. Epub 2015 Jan 29.</citation>
    <PMID>25635001</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <results_first_submitted>January 7, 2016</results_first_submitted>
  <results_first_submitted_qc>January 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2016</results_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quadriceps Muscle</keyword>
  <keyword>RNA, Messenger</keyword>
  <keyword>Hypertrophy</keyword>
  <keyword>Electric Stimulation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: High-force Muscle Stimulation</title>
          <description>High-force muscle stimulation</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Low-force Muscle Stimulation</title>
          <description>Low-force muscle stimulation</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: Sequential Low-force and High-force Muscle Stimulation</title>
          <description>Sequential low-force and high-force muscle stimulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: High-force Muscle Stimulation</title>
          <description>High-force muscle stimulation</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Low-force Muscle Stimulation</title>
          <description>Low-force muscle stimulation</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: Sequential Low-force and High-force Muscle Stimulation</title>
          <description>Sequential low-force and high-force muscle stimulation</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.33" spread="7.45"/>
                    <measurement group_id="B2" value="36.0" spread="32.3"/>
                    <measurement group_id="B3" value="32.3" spread="9.1"/>
                    <measurement group_id="B4" value="32.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HF Muscle Force</title>
        <description>Muscle force evoked during high-force muscle stimulation</description>
        <time_frame>up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: High-force Muscle Stimulation</title>
            <description>High-force muscle stimulation: Electrical stimulation of paralyzed muscle to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Low-force Muscle Stimulation</title>
            <description>Low-force muscle stimulation: Electrical stimulation of paralyzed muscle to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Sequential Low-force and High-force Muscle Stimulation</title>
            <description>Sequential low-force and high-force muscle stimulation: Electrical stimulation of paralyzed muscle to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.</description>
          </group>
        </group_list>
        <measure>
          <title>HF Muscle Force</title>
          <description>Muscle force evoked during high-force muscle stimulation</description>
          <units>Newtons (N)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="5.9"/>
                    <measurement group_id="O3" value="30.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LF Muscle Force</title>
        <description>Muscle force evoked during low-force muscle stimulation</description>
        <time_frame>up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: High-force Muscle Stimulation</title>
            <description>High-force muscle stimulation</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Low-force Muscle Stimulation</title>
            <description>Low-force muscle stimulation</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Sequential Low-force and High-force Muscle Stimulation</title>
            <description>Sequential low-force and high-force muscle stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>LF Muscle Force</title>
          <description>Muscle force evoked during low-force muscle stimulation</description>
          <units>N (newtons)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="26.72" spread="19.03"/>
                    <measurement group_id="O3" value="27.58" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skeletal Muscle Gene Regulation: MSTN</title>
        <description>Messenger ribonucleic acid (mRNA) expression fold-change for myostatin (MSTN). Fold change: post-intervention expression / pre-intervention expression. Values greater than 1.0 indicate up-regulation. Values less than 1.0 indicate down-regulation.</description>
        <time_frame>up to 1 year</time_frame>
        <population>Only a subset of Arm 1 and Arm 3 participants underwent biopsy: we achieved statistical power with these subsets and further biopsies were not warranted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: High-force Muscle Stimulation</title>
            <description>High-force muscle stimulation</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Low-force Muscle Stimulation</title>
            <description>Low-force muscle stimulation</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Sequential Low-force and High-force Muscle Stimulation</title>
            <description>Sequential low-force and high-force muscle stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Muscle Gene Regulation: MSTN</title>
          <description>Messenger ribonucleic acid (mRNA) expression fold-change for myostatin (MSTN). Fold change: post-intervention expression / pre-intervention expression. Values greater than 1.0 indicate up-regulation. Values less than 1.0 indicate down-regulation.</description>
          <population>Only a subset of Arm 1 and Arm 3 participants underwent biopsy: we achieved statistical power with these subsets and further biopsies were not warranted.</population>
          <units>fold-change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".56" spread=".06"/>
                    <measurement group_id="O3" value=".67" spread=".40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skeletal Muscle Gene Expression: PPARGC1A</title>
        <description>Messenger ribonucleic acid (mRNA) expression fold-change for peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PPARGC1A). Fold change: post-intervention expression / pre-intervention expression. Values greater than 1.0 indicate up-regulation. Values less than 1.0 indicate down-regulation.</description>
        <time_frame>up to 1 year</time_frame>
        <population>Only a subset of Arm 1 and Arm 3 participants underwent biopsy: we achieved statistical power with these subsets and further biopsies were not warranted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: High-force Muscle Stimulation</title>
            <description>High-force muscle stimulation: Electrical stimulation of paralyzed muscle to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Low-force Muscle Stimulation</title>
            <description>Low-force muscle stimulation: Electrical stimulation of paralyzed muscle to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Sequential Low-force and High-force Muscle Stimulation</title>
            <description>Sequential low-force and high-force muscle stimulation: Electrical stimulation of paralyzed muscle to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Muscle Gene Expression: PPARGC1A</title>
          <description>Messenger ribonucleic acid (mRNA) expression fold-change for peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PPARGC1A). Fold change: post-intervention expression / pre-intervention expression. Values greater than 1.0 indicate up-regulation. Values less than 1.0 indicate down-regulation.</description>
          <population>Only a subset of Arm 1 and Arm 3 participants underwent biopsy: we achieved statistical power with these subsets and further biopsies were not warranted.</population>
          <units>fold-change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.46" spread=".64"/>
                    <measurement group_id="O3" value="4.97" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: High-force Muscle Stimulation</title>
          <description>High-force muscle stimulation</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Low-force Muscle Stimulation</title>
          <description>Low-force muscle stimulation</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: Sequential Low-force and High-force Muscle Stimulation</title>
          <description>Sequential low-force and high-force muscle stimulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard K. Shields PhD, PT</name_or_title>
      <organization>University of Iowa / Iowa City VA Medical Center</organization>
      <phone>319-335-9791</phone>
      <email>richard-shields@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

